Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 / Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(ASSURE) | completed | Phase 3 | 1,943 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 |
| clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05820087 | The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)(#HOPE4KIDNEY) | active not recruiting | N/A | 67 | HistoSonics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06770855 | Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC) | not yet recruiting | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02848768 | Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma(RTKI) | completed | — | 45 | Rennes University HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | SillaJen, Inc.INDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657325 | Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma | recruiting | — | 110 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03455452 | Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer(WITNESS) | completed | — | 623 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04941768 | An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | completed | — | 105 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT04944550 | New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.(CICLOP) | completed | — | 20 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07038733 | Investigation of Lymph Node Biology in Kidney Cancer(LN-RCC) | recruiting | N/A | 33 | Yale UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03630536 | TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative | completed | — | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05858749 | A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). | completed | — | 494 | PfizerINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | recruiting | Phase 2 | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00715442 | Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04495257 | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | completed | Phase 1 | 26 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07037004 | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07633353 | Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study(UTUC PROVE) | enrolling by invitation | — | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04322955 | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition(Cyto-KIK) | active not recruiting | Phase 2 | 38 | Mark SteinOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07018037 | Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma(TTV ccRCC) | recruiting | — | 20 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03747133 | SABR for Renal Tumors | recruiting | N/A | 90 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04085237 | ESP Block for Laparoscopic Nephrectomy Surgeries(ESPB) | terminated | N/A | 10 | McMaster UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06783348 | Radiopharmaceutical Treatment of Advanced Kidney Cancer(RENALUT) | recruiting | Phase 2 | 48 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627464 | Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy(ALTER-UC-011) | not yet recruiting | Phase 2 | 144 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00352534 | Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor | completed | Phase 3 | 808 | Children's Oncology GroupNETWORK | 7 | Jun 3, 2026 | clinicaltrials |
| NCT00945009 | Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor | completed | Phase 3 | 249 | Children's Oncology GroupNETWORK | 6 | Jun 3, 2026 | clinicaltrials |
| NCT03092856 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | active not recruiting | Phase 2 | 62 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624578 | Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study(REIN-TEP PSMA) | withdrawn | N/A | 0 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT02526511 | Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors | completed | N/A | 75 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02210117 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | active not recruiting | Early Phase 1 | 104 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05361434 | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults(CaboCombo) | completed | — | 311 | IpsenINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06090331 | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2026source: clinicaltrials